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Abstract. 
Understanding the safety of medication use during pregnancy relies on observational 
studies: however, confounding in observational studies poses a threat to the validity of 
estimates obtained from observational data. Newer methods, such as marginal structural 
models and propensity calibration, have emerged to deal with complex confounding 
problems, but these methods have seen limited uptake in the pregnancy medication 
literature. In this article, we provide an overview of newer advanced methods for 
confounding control and show how these methods are relevant for pregnancy medication 
safety studies. 
 
Key Points. 
• Studies of the safety of medication use during pregnancy depend mainly on 
observational studies, which are subject to confounding bias. 
• Novel methods for confounding control have seen limited uptake in the pregnancy 
medication safety literature. 
• Application of novel methods is necessary to appropriately address the complex 
confounding scenarios found in pregnancy studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 2 of 37
http://mc.manuscriptcentral.com/pds
Pharmacoepidemiology and Drug Safety
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
3 
 
 
More than half of all pregnant women in the US and other western countries take 
medication during pregnancy,1–3 making studies of the safety and efficacy of medications 
a pressing public health concern. Studying medication safety in pregnancy presents 
particular challenges: effects of medication exposure on fetal development can be 
unpredictable, vulnerability to exposure changes during pregnancy, and outcomes of 
interest may occur early in fetal development but be detected later, as is the case for birth 
defects.4 In the general population, knowledge of medication efficacy and safety is 
primarily based on randomized controlled trials. However, randomized trials routinely 
exclude pregnant women due to uncertainties about the effects of medications on fetal 
development, meaning that studies of medication safety in pregnancy must rely on 
reproductive toxicity studies in animals and on observational data in humans. Several 
landmark cases have taught us that animal models for teratogenicity do not necessarily 
translate to humans, as was the cas  in the thalidomide disaster. Observational studies, 
which can include data sources such as pregnancy and birth cohorts, administrative and 
registry data, and pregnancy and birth reg stries, represent important opportunities for 
understanding the risks and benefits for medication use in pregnancy, and in 2005, the 
Food and Drug Administration (FDA) acknowledged that observational studies are the 
best method for assessing the maternal and fetal safety of using medication during 
pregnancy.5 However, confounding is a major source of bias in observational studies, and 
as such, it is the focus of this paper. Recent years have seen the rapid development of 
advanced methods for dealing with confounding; yet, uptake of these methods has been 
slow in the pregnancy medication literature. This is unfortunate, because in the pregnancy 
medication research field, it is arguably especially important that researchers make use of 
the best methods for confounding control and causal inference, because data from 
randomized controlled trials are unlikely to  be available, and the consequences for 
getting the wrong answer are so profound: failing to detect true effects of medication 
exposure can have enormous effects in the population, and falsely raising the alarm for a 
safe drug can result in women forgoing needed therapies and in some cases, terminating 
wanted pregnancies.5  
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In this paper, we advocate for a greater use of advanced methods for confounding 
control in the pregnancy medication safety research field, and provide an overview of 
these methods under the following framework:  
(1) How does this method help us to make fair comparisons between the exposed 
and unexposed groups? 
(2) How has this method been applied in the pregnancy medication literature?  
(3) How is the method used in practice? 
(4) What are the important assumptions for this method?  
(5) What are the major strengths and limitations of the method? 
Table 1 provides an outline of pregnancy medication studies using advanced methods to 
deal with confounding. This paper gives a useful reference for both students and 
experienced researchers who wish to gain new skills in advanced methods for 
confounding control.  
 
Confounders and Causal Inference 
First, a definition of confounding: a confounder is a factor in a study that (a) is 
associated with (and precedes) the medication exposure, (b) is a risk factor for the 
outcome, and (c) does not lie on the causal pathway between medication use and 
outcome. In randomized studies, we can be reasonably confident that confounders (both 
measured and unmeasured) are balanced between exposed and unexposed groups, 
whereas in observational studies, this is almost certainly not the case. If the distribution 
of confounders is different for the exposed and unexposed groups, estimates of effect 
may be biased. Taking confounding into account is essential in observational studies. 
Further, it is important for researchers to carefully consider the timing of the confounder 
relative to the exposure and outcome.4 
Second, we focus on the definition of causal effects arising from the 
counterfactual: that is, we would like to understand what the experience of women who 
took a medication during pregnancy would have been, had she not taken the medication. 
In this definition, confounding exists when women who did not take the medication of 
interest are not adequate stand-ins for the women who did. The counterfactual approach 
to confounding clarifies a concept that researchers understand intuitively: that we must 
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strive to make fair comparisons between exposed and unexposed groups. For example, 
for researchers studying the effects of antidepressant exposure on congenital 
malformations, comparing a group of women using antidepressants who also have severe 
depression to a group of women with no antidepressant use and no history of depression 
would be an unfair comparison: the unexposed group is not an adequate stand-in for the 
experience of women using antidepressants. 
 
Confounding in pregnancy medication studies 
Application of advanced confounding control methods begins with a thorough 
review of the literature and consultation with subject-area experts. Directed acyclic 
graphs (DAGs) provide a graphical means to represent the causal structure the 
investigator believes is present,6 and guide study design, data collection, and analysis. 
Figure 1 is an example DAG showing one possible causal model for prenatal 
antidepressant exposure and childhood neurodevelopment. This DAG shows potential 
biasing paths, including confounders (other psychiatric illness, other psychiatric 
medication use, depression severity, and genetics) which should be controlled as far as 
possible, as well as a mediator (gestational age), and a collider (live birth). Several non-
biasing paths, including a risk factor for the outcome that is unrelated to the exposure 
(child gender) and a predictor of exposure that is unrelated to the outcome (pre-
pregnancy antidepressant use) are also shown. Obtaining unbiased effect estimates 
requires investigators to identify and control confounding, insofar as it is possible to do 
so, while avoiding bias from inappropriate control for colliders and mediators and loss of 
precision or confusing interpretation of estimates arising from control for factors only 
related to the exposure or outcome but not both.7 
Specific types of confounders arise often enough that they are grouped together. 
Confounding by indication challenges the researcher to distinguish whether the outcome 
of interest is caused by the drug under study or the disorder being treated. Including a 
disease comparison group (women with the same disease and ideally the same disease 
severity, but not treated with the drug), or comparing drug use across different 
indications, offers advantages over studies comparing exposed cases to healthy controls 
only. Confounding by concomitant medication use occurs when women use multiple 
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medications, and it is the concomitant medication, not the index drug, that is responsible 
for the observed effects. Other potential confounders include maternal factors such as 
lifestyle, paternal characteristics, genetic risk, and complex familial factors like home 
environment. These confounders may be measured with varying degrees of completeness 
or quality, depending on the data source, study design, and difficulty of measurement. 
We have grouped the available advanced methods for confounding control into categories 
based on qualities of confounder data, including whether and when it was measured. 
 
I. Methods for measured confounders 
In Box 1 (supplemental material), we include a simplified illustration of 
confounding by measured factors and the methods to address confounding. 
Confounder summary scores and marginal structural models are useful for 
measured confounders. These methods reduce a large amount of information about an 
individual into a single summary score: in short, two individuals can have the same 
summary score but different individual confounder values (e.g., a woman with a 
predicted probability of taking an antidepressant during pregnancy of 0.5 might be an 
unemployed smoker with anxiety, or a non-smoking lawyer with depression), but because 
their distribution of confounders is equivalent, any differences in outcome will be 
attributable only to exposure to the drug of interest. Fair comparisons between exposure 
groups can then be made because within each stratum of exposure, the distribution of 
common causes of exposure and outcome are the same. 
 
I.A. Propensity Scores (and other confounder summary scores) 
Studies of medication safety in pregnancy often require consideration of, and 
adjustment for, a large number of confounders. The propensity score, which is the 
probability of exposure given observed confounders,8 reduces the set of confounders to a 
single confounder summary score. Propensity scores are more commonly used in the 
medical literature; however, other confounder summary score methods, including disease 
risk scores9 (preferred in the case of rare exposures) and polygenic risk scores10 (useful 
for cases when genetic confounding is of high concern) are available. 
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Propensity scores are typically constructed using multivariable logistic regression, 
where exposure is the dependent variable and confounders are the independent variables. 
The propensity score model should include variables that are confounders or predictors of 
the outcome; inclusion of factors that are only predictors of exposure will increase 
variance without decreasing bias.11 High dimensional propensity scores, which include 
thousands of variables identified through computational algorithms, may also be useful 
for adjusting for unmeasured confounders, if the measured variables are partial proxies 
for the unmeasured confounders.12 The propensity score can be used to match, stratify, 
adjust, or weight the outcome model. Propensity scores, including high dimensional 
propensity scores, have seen increased uptake in the pregnancy literature, i.e. safety 
studies on ondansetron,13 lithium,14 antidepressants,15 and statins16 in pregnancy, but their 
use is still minimal compared to multivariable regression (Table 1). Box 1, in the 
supplemental material, gives a simplified explanation of propensity score matching and 
weighting. 
Assumptions: Use of propensity scores requires several assumptions, including 
exchangeability (no unmeasured confounding) and positivity (nonzero probability of 
treatment). Neither assumption is formally testable. Positivity can be addressed by 
ensuring that the women in the sample all have the indication for the medication (i.e., if 
assessing safety of antidepressants, all women in the sample should be at risk for 
treatment) and that no individuals with clear contraindications are included. 
Exchangeability is never assured; however, sensitivity analyses can yield estimates for 
how vulnerable an effect estimate may be to unmeasured confounding.  
Strengths and Limitations: Propensity scores and other summary scores reduce 
many confounders to a single factor, which is especially relevant when working with a 
common treatment and rare outcome. They also separate the design of the study 
(modeling confounding) from modeling the outcome, reducing the unconscious tendency 
to “peek” at the outcome before the final model is decided upon.17 However, scenarios in 
which the exposure (or disease, in the case of disease risk scores) is rare, summary scores 
do not perform particularly well, and of course, these methods do not address 
unmeasured confounding.18 In addition, use propensity score methods in case control or 
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case cohort studies may produce the appearance of effect modification and/or result in 
residual confounding, particularly when the sample size is small.19  
  
I.B. Marginal Structural Models 
Marginal structural models (MSM) address time-varying exposure and 
confounding.20,21 Rules for confounder adjustment state we must adjust for confounders 
or common causes of the exposure and outcome, but should not adjust for factors on the 
causal pathway. In the case of time-varying exposure and confounding, we encounter a 
double bind: factors that are confounders in one part of the causal structure are mediators 
in another part (Figure S1A). For example, when studying the safety of antidepressants, 
we may wish to control for depression severity. However, antidepressant use in earlier 
pregnancy predicts depressive symptoms in later pregnancy, which will also predict 
subsequent antidepressant use. Standard adjustments for depression severity will always 
be biased in this scenario.  
Central to the MSM is the inverse probability of treatment weight (IPTW). At 
each measurement time t, the investigator uses logistic regression to construct the 
numerator (probability of exposure) and denominator (probability of exposure, given 
baseline predictors and history of exposure at time t-1). The exposed individuals are 
given a weight equal to the inverse of the probability of exposure, and the unexposed are 
given a weight equal to the inverse of one minus the probability of exposure.22 The total 
weight is the product of the weights at each time point, and analyses are conducted in the 
weighted population, or pseudo-population, in which individuals who are likely to be 
exposed (conditional on measured confounders) are given less weight, while those who 
are unlikely to be exposed are given more weight, resulting in balance of measured 
confounders within strata of exposure.  
Use of marginal structural models for pregnancy medication safety studies 
remains rare,23,24 despite examples where timing of exposure is of great importance, and 
exposure is conditional on time-varying confounders, such as other medication use, 
changes in health status, or changes in indication or severity of disease.  
Assumptions: Under assumptions of positivity, exchangeability, and consistency, 
the MSM will give an unbiased estimate of the effect of the exposure on the outcome. 
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These assumptions are not formally testable, although assessment of the positivity 
assumption may include evaluation of the IPTW for extreme weights, and progressive 
truncation of the weights to determine whether extreme weights are highly influential.25 
When important confounders are unmeasured or incompletely measured, marginal 
structural model methods will not provide unbiased effect estimates. 
Strengths and Limitations: The key strength of the MSM is that it allows 
consideration of time-varying exposure and confounding, which is highly relevant in 
pregnancy research due to the changes in fetal vulnerability through the course of 
pregnancy, and the tendency of women to change their medication use during pregnancy, 
even for chronic medications.26 However, when the treatment-covariate association is 
very strong, resulting in extreme IPTWs,  MSMs can produce very wide confidence 
intervals which fail to include the true effect, especially for smaller sample sizes.25 
 
II. Methods for incomplete confounder data 
 Important confounders may be unmeasured in some databases, and failure to 
adjust for these unmeasured confounders results in biased effect estimates (Figure S1B). 
In some situations, the confounder of interest was not measured in the original dataset, 
but was measured in a sample that is a reasonable stand-in for the original sample. In this 
scenario, it is still possible to adjust for the confounder, even if the outcome has not been 
measured in this sample, using propensity score calibration.27–29 Propensity score 
calibration is a method based on regression calibration30 that offers an additional 
advantage over other methods of calibration, which examine residual confounding by a 
single variable,31 because it allows for adjustment of the joint effects of multiple 
confounders. For example, in a study of triptan safety, we used a cross-sectional study to 
jointly adjust estimates for migraine severity and type.32  
 In this method, two propensity scores must be calculated: the error-prone 
propensity score (estimated in both the main and validation studies, including only the 
confounders available in the main study) and the gold-standard propensity score 
(estimated in the validation study, including all confounders). The outcome model is 
fitted using the difference between the error-prone and gold standard propensity scores to 
calibrate effect estimates.  
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Assumptions: In addition to the assumptions of propensity score models, outlined 
previously, propensity score calibration also assumes that the validation sample (whether 
internal or external) is a valid stand-in for the main sample and that the measurement 
error model is correctly specified.27,28 Propensity score calibration depends on an 
assumption of surrogacy, which means that the error-prone propensity is an adequate 
surrogate for the gold-standard propensity score.33 If the outcome is not measured in the 
validation study, the surrogacy assumption is not formally testable, although it has been 
shown that violations of surrogacy occur when the direction of confounding differs 
between the main and validation studies,27 and that bias arising from violations of 
surrogacy can be predicted.33  
Other methods exist for addressing partially-missing confounder data, including 
weighting by the inverse probability of missingness, as well as standard imputation 
techniques, and a comparison of these methods with propensity score calibration showed 
little material differences in bias reduction.34  
Strengths and Limitations: The main strength of propensity score calibration 
allows for adjustment for additional confounders, if they were not measured completely 
in the original study, even if outcome data are not available, and they have a strong 
theoretical base in the regression calibration literature. However, calibration methods fail 
when unmeasured confounding is strong, and violations of the surrogacy assumption may 
result in increased bias.   
 
 
III. Methods for unmeasured confounding 
Information on confounders may be too difficult to adequately measure (e.g., 
family environment or parenting style) or too costly (e.g. deep sequencing genetic data 
for large samples). The methods discussed below exploit aspects of observational data to 
control for measured and unmeasured confounders. Because siblings share substantial 
hereditary and environmental risk factors, comparing the outcomes of two siblings with 
discordant in utero exposure experiences is fairer than comparing two unrelated 
individuals.  
III.A. Sibling Comparison Designs  
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If the unmeasured confounders can reasonably be thought of as shared between siblings 
(see Figure S1C for illustration), then studies examining sibling groups where medication 
exposure varies within sibling groups allows researchers to remove bias due to shared 
confounders.35–37 If, for example, we believe that any observed differences in autism risk 
between children with and without prenatal exposure to antidepressants is due to 
inherited genetic risk from the mother, then comparing the risk of autism between pairs 
of siblings with discordant prenatal exposure should be less biased than comparing 
autism risk between unrelated exposed and unexposed groups. 
 There has been substantial uptake of sibling study designs in the pregnancy 
medication safety literature in recent years, particularly in studies examining the safety of 
antidepressants, where the main concern is separating the underlying genetic and familial 
components of depression from exposure to antidepressant medications.38,39  
Assumptions: Use of sibling designs is most appropriate when confounders that 
are shared between siblings are more important than those that are unshared,36 and that 
there are no carryover effects between siblings.40  
Strengths and Limitations: Sibling designs have the advantage of controlling 
confounding, both measured and unmeasured, that is shared between siblings. However, 
failing to control for important unshared confounders between siblings results in 
increased bias; sibling studies are also more vulnerable to bias from measurement error 
than non-sibling studies.36 
III.B. Instrumental Variables 
Instrumental variable (IV) methods 41,42 require identifying a variable or variables 
whose effect on the outcome occurs only through the exposure: an example of a perfect 
instrument is a coin toss assigning an individual to exposure or non-exposure, while 
commonly used (and less strong) instruments include provider prescription preference 
and distance from health care services. One example of instrumental variable methods 
used in pregnancy medication research is a study of antidepressant (AD) efficacy during 
pregnancy using provider preference, calendar time as a function of recent FDA 
recommendations, and geographic differences in AD use as instruments; however, these 
instruments were only weakly associated with the treatment, which may have contributed 
to the equivocal findings from this study.43 IV studies are most often conducted using a 
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two stage least squares methods, where in the first stage, the instrument or instruments 
are used as explanatory variables in a model predicting the exposure, and the predicted 
values from this first stage are used as predictors in a model of the outcome.  In general, 
identifying a strong instrument that meets all of the necessary assumptions is extremely 
challenging, which has likely contributed to the slower adoption of this method. 
Mendelian randomization, which uses a genetic marker as an instrument, is a subtype of 
instrumental variable analysis;44 while Mendelian randomization has not yet been used in 
pregnancy medication studies, studies estimating the effect of alcohol use during 
pregnancy on later neurocognitive outcomes have used the genetic variants encoding 
alcohol dehydrogenase, an enzyme that metabolizes alcohol, with some success.45 
Assumptions: Instrumental variable analyses allow for an unbiased effect estimate 
under certain strict assumptions: (i) the instrument has a causal effect on the exposure of 
interest, (ii) the instrument effects the outcome only through the exposure of interest, not 
through any other pathways, (iii) there are no common causes or confounders of the 
instrument-outcome pathway (Figure S1D). 
Strengths and Limitations: Instrumental variable analyses address bias from 
measured and unmeasured confounders, and so instruments that meet all the assumptions 
will mimic the results from a randomized trial. However, estimates are highly sensitive to 
violations of untestable assumptions, and violations may produce bias amplification; for 
example, if there is unmeasured confounding of the instrument and outcome.41 
 
 
Figure 2 guides readers through the process of selecting a method or methods, 
based on categorization of confounder data according to availability and timing.  The 
most important first step is to draw a DAG or DAGs that represent the proposed causal 
mechanism, without regard to availability of data on confounders: if a confounder is 
important, it should be included in the DAG, even if the study did not collect data on it. 
The next step is to determine which confounders are available in your study, and whether 
the data support the appropriate analytic method. For example, if your DAG shows that in 
theory, medication use and confounders vary over time, but your data shows no such 
variation, a MSM approach should not be used. In addition to addressing measured 
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confounders, methods for dealing with unmeasured or incompletely measured 
confounders should be considered, and again, the researcher must determine whether the 
data available to her can support the analytic method: if the data cannot identify siblings, 
or if the assumptions of instrumental variables are clearly not met, these methods cannot 
be used. Finally, quantitative bias analysis should be employed as a sensitivity analysis. 
Most importantly, we urge researchers to consider potential sources of confounding 
regardless of whether they were measured in the data, and to choose the methods most 
suited to the data they have available: Figure 2 suggests a systematic way of approaching 
this process. 
 A reference to selected software for the methods discussed in this paper is 
included as part of the supplemental material. 
Discussion 
 Studies of medication use during pregnancy depend upon observational data to 
answer critical questions of safety and efficacy. More traditional methods for 
confounding control, such as stratification, restriction, matching, and adjustment have 
been described in great detail elsewhere, and because of this we have not discussed them 
here. These older methods have their place in observational research, but as our 
understanding of the complexities of bias has progressed, so has our understanding of the 
limitations of these methods. The advanced methods described in this paper were 
developed to address specific confounding problem, and are necessary to reduce bias, and 
ultimately to produce the best information possible to health care providers and pregnant 
women. Using these methods can produce substantially different results from traditional 
methods, such as when we compare the cohort and sibling studies of antidepressant 
safety,38,39,46 the regression-adjusted to the marginal structural model estimates for triptan 
safety,23 propensity calibrated estimates to standard propensity score methods,32 or 
including standard regression, propensity score methods, sibling controls, and negative 
paternal controls in one study.47  
Aside from a few examples, these methods have seen slow uptake in the 
pregnancy medication research literature. This is almost certainly due to a sense of 
caution about methods that can seem opaque, especially upon first encounter with the 
seminal methods paper describing the technique. It is true that caution is necessary when 
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applying novel methods. However, it is also true that the more standard regression 
methods require similar assumptions to the more advanced methods discussed in this 
paper. Perhaps it is true that familiarity with standard methods had bred, if not contempt, 
then certainly comfort. If readers find that their research question fits well with one of the 
scenarios described in this paper, we suggest approaching the problem by tackling the 
citations given for the technique. The techniques we describe in this paper have their 
roots in standard regression techniques and can be implemented with standard software. 
While this paper focuses on bias due to confounding, other sources of bias such as 
exposure and/or outcome misclassification48 and selection bias49, as well as seasonal 
effects,50 can also distort effect estimates. This paper is not intended to be an exhaustive 
discussion of all possible methods for confounding control. New techniques are being 
developed all the time, and many of these, such as g-estimation51,52 and targeted 
maximum likelihood estimation,53 have not yet been implemented in the pregnancy 
medication literature. Quantitative bias analysis can help researchers account for bias due 
to systematic errors in their data, and these methods are easily implemented with standard 
software.54 Further, the methods discussed herein are not mutually exclusive, and can be 
used in combination with each other: combining propensity scores with instrumental 
variables43 or marginal structural models with quantitative bias analysis23 gives far more 
information about the probable range of effect estimates than any of these methods alone. 
Observational pharmacoepidemiology studies are vital to our understanding of the 
safety of medications in pregnancy, but as they are based on observational data, great 
care must be taken in the analysis and interpretation of data to minimize confounding and 
bias. In all pharmacoepidemiological studies sources of bias should be acknowledged and 
discussed, and preferably quantified by performing sensitivity analysis of estimates under 
an array of assumptions about possible bias directions and magnitudes. 
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FIGURE LEGENDS 
 
Figure 1. Conceptual model for the effect of prenatal SSRI exposure on attention 
deficit/hyperactivity disorder (ADHD), including a set of important confounders 
(depression severity, concomitant medication use, genetics), a potential mediator 
(gestational age), a collider (live birth), and factors related only to the exposure (pre-
pregnancy SSRI use) or the outcome (child gender). 
 
Figure 2. Choosing methods for confounding control
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Table 1. Examples of application of advanced confounding control methods in the pregnancy medication safety literature. 
Medication &  
Study Reference 
Outcome Confounder(s) Confounding 
Problem(s) 
Method(s) Employed  
   
T
im
e-varying 
 
C
om
plex/ H
igh- 
dim
ensional 
U
nm
easured 
confounders 
P
ropensity scores/ 
sum
m
ary scores 
M
arginal 
structural m
odels 
P
ropensity 
calibration 
S
ibling/fam
ily 
studies 
Instrum
ental 
variables 
Ondansetron 
(Pasternak, Svanström, & 
Hviid, 2013) 
Malformations 
 
Nausea/vomiting; maternal characteristics, 
comorbidities, other medications, 
pregnancy history. 
 x  x     
Lithium 
(Patorno et al., 2017) 
Cardiac 
Malformations 
Maternal comorbidities, other medications, 
maternal characteristics.  x  x     
Statins 
(Bateman et al., 2015) 
Malformations Maternal characteristics, obstetric and 
medical conditions, other medications. 
 x  x     
Triptans 
(Wood, Lapane, et al., 2015) 
Neurodevelopment Other medications (time-varying), maternal 
characteristics; migraine severity. 
x    x    
Iron supplementation 
(Bodnar, Davidian, Siega-
Riz, & Tsiatis, 2004) 
Anemia Maternal baseline characteristics; gastric 
symptoms; serum ferritin and hemoglobin 
concentration. 
x    x    
Triptans 
(Wood, Frazier, Nordeng, & 
Lapane, 2015) 
Neurodevelopment Other medications, maternal characteristics; 
migraine severity, attitudes about 
medication use. 
 x x x  x   
SSRI 
(Nezvalová-Henriksen et al., 
2016; Viktorin et al., 2016) 
Gestational age, 
birth weight 
Family factors, maternal depression; 
illnesses,  
other medications. 
 x  x   x  
Anti-epileptic drugs 
(Bech et al., 2014) 
Spontaneous 
abortion 
Severity of maternal epilepsy; maternal 
characteristics, environmental exposures, 
comorbidities. 
  x    x  
SSRI 
(Swanson et al., 2015) 
Maternal depression 
relapse 
Maternal depression severity; 
comorbidities, other medications, maternal 
characteristics, proxies for severity. 
 x x x    x 
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Figure 1. Conceptual model for the effect of prenatal SSRI exposure on attention deficit/hyperactivity 
disorder (ADHD), including a set of important confounders (depression severity, concomitant medication 
use, genetics), a potential mediator (gestational age), a collider (live birth), and factors related only to the 
exposure (pre-pregnancy SSRI use) or the outcome (child gender).  
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Supplemental Material 
 
Figure S1. Directed acyclic graphs (DAGs) for (a) Time varying confounding: time-varying exposure A, 
outcome Y, baseline confounders C and time-varying confounders TVC at times 0, 1, and 2; (b) 
Unmeasured confounding: exposure A, outcome Y, and measured C and unmeasured U 
confounders; (c) Sibling study design, for siblings (1 and 2), with exposure A, outcome Y, and 
confounders C of AY, and shared unmeasured factors which cause C, A, and Y; (d) Instrumental 
variable (IV) which affects the outcome Y only through the exposure A and therefor controls both 
measured confounders C and unmeasured confounders U. 
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Software resources 
Method Software References 
Propensity Scores SAS Macros “psmatch_multi”, “cem” available for public 
use 
 
Notes: all major software 
packages can output 
predicted probabilities after 
logistic regression to give 
propensity score, which can 
be used to calculate weights 
and strata. Additional 
software can assist with 
matching, 
Stata teffects command available in v13 and later; user-
written commands “pscore”, “match”, “cem”, 
“psmatch2” for earlier versions 
SPSS No formal support; “PS Matching” add-on calls 
“matchit” package from R.SPSS only supports 
frequency weights except through the complex 
survey sampling add-on! Software may round 
propensity weight to the nearest whole number 
and use it as a frequency weight without returning 
an error message.  
R Packages “twang” “cem” “optmatch” “matchit” and 
“matching” available for download 
Marginal Structural Models SAS After creating joint IPTW in data step, use “weight” 
option in standard outcome analyses. 
Notes: weights estimated 
from pooled logistic 
regression, similarly to PS 
methods above. Notes above 
regarding weights in SPSS also 
apply here. 
Stata After creating joint IPTW in data step, use 
“pweight” option in standard outcome analyses. 
SPSS See notes above on propensity score weighting 
R After creating joint IPTW in data step, specify 
appropriate probability weight option (varies by 
outcome model type) 
Propensity Calibration SAS Carry out through regression calibration; “Blinplus” 
macro available for download 
Notes: technique developed 
using SAS macros. Other 
software supports regression 
calibration (noted at right) 
but has not been testing in 
the unmeasured confounding 
application. 
Stata User-written command “rcal” performs regression 
calibration 
SPSS Not available. 
R “iWeigReg” package after propensity score 
estimation. 
Sibling Comparison SAS PROC MIXED and PROC NLMIXED 
 
Notes: implemented using 
standard mixed model 
software 
Stata Xtreg command 
SPSS MIXED command 
R Multiple options for downloadable packages, 
including “lme” and “nlme” 
Instrumental Variable(s) SAS PROC SYSLIN, PROC MODEL, PROC CALIS 
 
Notes: multiple approaches 
to IV analyses. Two stage 
least squares approaches are 
Stata “IVRegress” included from v13 on; user written 
package “ivreg2” fits 2sls models; other packages 
available for extended applications. 
SPSS 2SLS command  
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most appropriate for linear 
outcomes; non-linear 
outcomes require special 
consideration, particularly 
with respect to standard 
errors. 
R “tsls” package 
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